HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors

European Journal of Immunology

Volumn 46, Issue 2, 2016, Pages 409-419

  Sottile, Rosa ^a,b   Pangigadde, Pradeepa N ^a,b   Tan, Thomas ^c   Anichini, Andrea ^d   Sabbatino, Francesco ^e   Trecroci, Francesca ^b   Favoino, Elvira ^e   Orgiano, Laura ^c   Roberts, James ^c   Ferrone, Soldano ^e   Kärre, Klas ^a   Colucci, Francesco ^c   Carbone, Ennio ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acquired drug resistance; Combination therapy; Cytotoxicity; Melanoma HLA; NK cell

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; HLA A ANTIGEN; IMIDAZOLE DERIVATIVE; OXIME; PROGRAMMED DEATH 1 LIGAND 1;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DEGRANULATION; DOWN REGULATION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TARGET CELL; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; CYTOTOXICITY; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANTIGENS, CD274; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HLA-A ANTIGENS; HUMANS; IMIDAZOLES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; UP-REGULATION;

EID: 84956958113     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445289     Document Type: Article

References (50)

1. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J. et al., Mutations of the BRAF gene in human cancer. Nature 2002. 417: 949-954.
2. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R. et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011. 364: 2507-2516.
3. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P. et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012. 380: 358-365.
4. Trunzer, K., Pavlick, A. C., Schuchter, L., Gonzalez, R., McArthur, G. A., Hutson, T. E., Moschos, S. J. et al., Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 2013. 31: 1767-1774.
5. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. and Wolchok, J. D., Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014. 65: 185-202.
6. Menzies, A. M. and Long, G. V., Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur. J. Cancer 2013. 49: 3229-3241.
7. Ngiow, S. F., Knight, D. A., Ribas, A., McArthur, G. A. and Smyth, M. J., BRAF-targeted therapy and immune responses to melanoma. Oncoimmunology 2013. 2: e24462.
8. Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J. and Hodi, F. S., The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin. Cancer Res. 2013. 19: 598-609.
9. Karre, K., Ljunggren, H. G., Piontek, G. and Kiessling, R., Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986. 319: 675-678.
10. Taniguchi, K., Petersson, M., Hoglund, P., Kiessling, R., Klein, G. and Karre, K., Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. USA 1987. 84: 3405-3409.
11. Hervieu, A., Mignot, G. and Ghiringhelli, F., Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology 2013. 2: e23714.
12. Fregni, G., Perier, A., Avril, M. F. and Caignard, A., NK cells sense tumors, course of disease and treatments: consequences for NK-based therapies. Oncoimmunology 2012. 1: 38-47.
13. Li, H., Lakshmikanth, T., Garofalo, C., Enge, M., Spinnler, C., Anichini, A., Szekely, L. et al., Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011. 10: 3346-3358.
14. Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G. and Cerwenka, A., Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011. 71: 5998-6009.
15. Carbone, E., Neri, P., Mesuraca, M., Fulciniti, M. T., Otsuki, T., Pende, D., Groh, V. et al., HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005. 105: 251-258.
16. Carlsten, M., Bjorkstrom, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M. et al., DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007. 67: 1317-1325.
17. Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C. et al., Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004. 64: 9180-9184.
18. El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D., Mackie, S. L., Morgan, A. W., Cook, G. et al., The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007. 67: 8444-8449.
19. Benson, D. M., Jr., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A. et al., The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010. 116: 2286-2294.
20. Gleason, M. K., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M. S., Cooley, S. A., Verneris, M. R. et al., Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012. 119: 3064-3072.
21. Ndhlovu, L. C., Lopez-Verges, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C. et al., Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012. 119: 3734-3743.
22. Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M. and Cerwenka, A., CTLA-4 Is expressed by activated mouse NK cells and inhibits NK cell IFN-gamma production in response to mature dendritic cells. J. Immunol. 2014. 192: 4184-4191.
23. MacFarlane, A. W. T., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E. et al., PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol. Res. 2014. 2: 320-331.
24. Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., Ferrone, C. R. et al., Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010. 70: 5213-5219.
25. Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F. et al., Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012. 18: 1386-1394.
26. Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Gorgens, A., Giebel, B. et al., Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int. J. Cancer 2013. 133: 1653-1663.
27. Schilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H. et al., Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann. Oncol. 2014. 25: 747-753.
28. Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M. et al., Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 2013. 123: 1371-1381.
29. Steinberg, S. M., Zhang, P., Malik, B., Boni, A., Shabaneh, T., Byrne, K., Mullins, D. W. et al., BRAF-inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol. Res. 2014. 2: 1044-1050
30. Orange, J. S., Natural killer cell deficiency. J. Allergy Clin. Immunol. 2013. 132: 515-525.
31. Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K., Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000. 356: 1795-1799.
32. Kim, S., Iizuka, K., Aguila, H. L., Weissman, I. L. and Yokoyama, W. M., In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 2000. 97: 2731-2736.
33. Knorr, D. A., Bachanova, V., Verneris, M. R. and Miller, J. S., Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 2014. 26: 161-72
34. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L. et al., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985. 313: 1485-1492.
35. Ali, T.H., Pisanti, S., Ciaglia, E., Mortarini, R., Anichini, A., Garofalo, C., Tallerico, R. et al., Enrichment of CD56(dim)KIR+CD57+ higly cytotoxic NK cells in tumor-infiltrated lymph nodes of melanoma patients. Nature Comm. 2014. 5: 5639.
36. Lakshmikanth, T., Burke, S., Ali, T.H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M. et al., NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 2009. 119: 1251-1263.
37. Barnstable, C. J., Bodmer, W. F., Brown, G., Galfre, G., Milstein, C., Williams, A. F. and Ziegler, A. et al., Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978. 14: 9-20.
38. Wang, X., Liang, B., Rebmann, V., Lu, J., Celis, E., Kageshita, T., Grosse-Wilde, H. et al., Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens 2003. 62: 139-148.
39. Wang, X., Campoli, M., Cho, H. S., Ogino, T., Bandoh, N., Shen, J., Hur, S. Y. et al., A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J. Immunol. Methods 2005. 299: 139-151.
40. Bandoh, N., Ogino, T., Cho, H. S., Hur, S. Y., Shen, J., Wang, X., Kato, S. et al., Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 2005. 66: 185-194.
41. Ogino, T., Wang, X., Kato, S., Miyokawa, N., Harabuchi, Y. and Ferrone, S., Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003. 62: 385-393.
42. Desai, S. A., Wang, X., Noronha, E. J., Zhou, Q., Rebmann, V., Grosse-Wilde, H., Moy, F. J. et al., Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J. Immunol. 2000. 165: 3275-3283.
43. Rebaï, N. and Malissen, B., Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens 1983. 22: 107-117.
44. Pellegrino, M. A., Ng, A. K., Russo, C. and Ferrone, S., Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 1982. 34: 18-23.
45. Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C. et al., Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 2003:198: 557-567.
46. Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E. et al., BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 2014. 20: 1965-1977.
47. Holzmann, B., Lehmann, J. M., Ziegler-Heitbrock, H. W., Funke, I., Riethmuller, G. and Johnson, J. P., Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. Int. J. Cancer 1988. 41: 542-547.
48. Ferrone, S. and Pellegrino, M. A., Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients. J. Natl. Cancer Inst. 1977. 58: 1201-1204.
49. Carey, T. E., Takahashi, T., Resnick, L. A., Oettgen, H. F. and Old, L. J., Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA 1976. 73: 3278-3282.
50. Cormier, J. N., Panelli, M. C., Hackett, J. A., Bettinotti, M. P., Mixon, A., Wunderlich, J., Parker, L. L. et al., Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer 1999. 80: 781-790.